BARCELONA, Spain, December 14, 2011 /PRNewswire/ --
The Contract Research Organization Kymos Pharma Services -specialised in analysis for the pharmaceutical, fine chemicals, biotechnological, veterinary, cosmetic and nutraceuticals sectors- has signed an agreement with the French multinational group Ipsen to take in a team of eight scientists from Ipsen R&D Centre in Sant Feliu de Llobregat (Barcelona).
For Kymos -with headquarters in Barcelona Science Park (PCB) and celebrating its 10th anniversary this year- this agreement allows the creation of an innovative area of R&D services in the field of bio molecules and biosimilars. Kymos will carry out this activity in a new immunology laboratory that will be opened in the PCB in early January 2012, conducting regulatory development projects for biotech companies.
"This new alliance consolidates the company's growth plan. The agreement also speeds up our international expansion plans, thus our company will be the only Spanish CRO and one of the few European ones that will be able to offer comprehensive services for biotech companies according to Good Laboratory Practices and Good Manufacturing Practices," says Joan Puig, strategic general manager of Kymos.
About KymosPharma Services
Kymos Pharma Services is a CRO located in the PCB that was created in 2001 by a group of professionals with over 10 years of experience in R&D of pharmaceutical companies. The company is focused on comprehensive analytical development studies for pharmaceutical and related sectors, as well as on bioanalysis of preclinical and clinical studies of small molecules. At present, its financial turnover exceeds 2.5 million Euros, with a staff of 35 professionals and direct activities in Portugal and Italy. The company has over 80 clients, including the main Spanish pharmaceutical companies and clients from several countries such as France, Great Britain and Switzerland.
Ipsen is a French biotechnology multinational group with sales of 1,100 million Euros that is listed on the Euronext stockmarket of Paris. It has 4,500 employees worldwide with offices in 50 countries and products sold in over 100. As a leader in the biotech sector, Ipsen assigns 20% of its profits to R+D focused on the development of peptides and proteins in the therapeutic areas of neurology, endocrinology, oncology and haematology.
SOURCE Kymos Pharma Services